Adimmune Corp

Common Name
Adimmune
Country
Taiwan
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
Ticker
4142
Exchange
TAIWAN STOCK EXCHANGE
Description
Adimmune Corp is a biotechnology company focusing on the research, production, and distribution of vaccines. Established as a significant player within the pharmaceutical industry, its primary functio...

Adimmune's GHG Emissions Data Preview

In 2023, Adimmune completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Adimmune has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2023202220212020 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 2
Unspecified Calculation Method
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Download Data

Verified Sources Behind Adimmune’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Adimmune’s data sources below and access millions more through our Disclosure Search.

a. Adimmune's ESG Report 2023
a. Adimmune's ESG Report 2023

Insights into Adimmune's Operational Emissions

In 2023, the total operational greenhouse gas (GHG) emissions of Adimmune amounted to 16,779 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a

Compared to 2022, the total operational greenhouse gas (GHG) emissions of Adimmune increased by 2.34%, suggesting that the company faced challenges in reducing its emissions from its core operations. a

Adimmune's Scope 1 Emissions Over Time

20212022202301.5 k3 k4.5 k6 ktCO2e+12%0%
  • Total Scope 1
  • Year-over-Year Change

What are Adimmune's Scope 1 emissions?

In 2023, the total Scope 1 emissions of Adimmune were 4,556 metric tons of CO₂ equivalent (tCO₂e). a

Has Adimmune reduced its Scope 1 emissions over time?

Since 2021, Adimmune's Scope 1 emissions have increased by 11.61%, reflecting a rising long-term trend in Scope 1 emissions over time. a

Compared to the previous year (2022), Adimmune's Scope 1 emissions remained relatively stable, indicating that Adimmune's emissions have plateaued with no significant change in its operational footprint. a

What are Adimmune's Scope 2 emissions?

In 2023, Adimmune reported Scope 2 greenhouse gas (GHG) emissions of 12,223 tCO₂e without specifying the calculation method. a

Has Adimmune reduced its Scope 2 emissions over time?

Since 2021, Adimmune's Scope 2 greenhouse gas (GHG) emissions ( Unspecified Calculation Method) have remained relatively stable, indicating that Adimmune 's emissions have plateaued with no significant change in its energy consumption footprint. a

Compared to the previous year (2022), Adimmune's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Adimmune 's emissions have plateaued with no significant change in its energy consumption footprint. a

What methodology does Adimmune use for Scope 2 reporting?

In 2023, Adimmune reported its Scope 2 emissions using an unspecified methodology. a

Adimmune's Scope 2 Emissions Over Time

20212022202303.5 k7 k10.5 k14 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Adimmune’s GHG Emissions Intensity Compared to Industry Peers

In 2023, Adimmune reported Scope 1 greenhouse gas (GHG) emissions of 4,556 tCO₂e and total revenues of USD 58 millions. This translates into an emissions intensity of 78.3 tCO₂e per millions USD. a

Adimmune's Scope 1 Emissions Intensity Compared to Peers

51001,00020,000500,000Scope 1 Emissions (tCO2e)0.251002,000100,000Revenues (Millions of USD)OBI PharmaYear: 2022Scope 1: 25 tCO2eRevenue: $M 0Scope 1 Intensity: 165.23 tCO2e/$MAscendis PharmaYear: 2024Scope 1: 62 tCO2eRevenue: $M 443Scope 1 Intensity: 0.14 tCO2e/$M3SBioYear: 2024Scope 1: 13,304 tCO2eRevenue: $M 1,364Scope 1 Intensity: 9.75 tCO2e/$MGubraYear: 2023Scope 1: 6 tCO2eRevenue: $M 30Scope 1 Intensity: 0.20 tCO2e/$MCSLYear: 2025Scope 1: 135,000 tCO2eRevenue: $M 23,347Scope 1 Intensity: 5.78 tCO2e/$MVIVA Biotech HoldingsYear: 2022Scope 1: 1,404 tCO2eRevenue: $M 373Scope 1 Intensity: 3.76 tCO2e/$MBiontechYear: 2024Scope 1: 2,405 tCO2eRevenue: $M 3,341Scope 1 Intensity: 0.72 tCO2e/$MCamurusYear: 2024Scope 1: 116 tCO2eRevenue: $M 169Scope 1 Intensity: 0.68 tCO2e/$MCytokineticsYear: 2024Scope 1: 242 tCO2eRevenue: $M 18Scope 1 Intensity: 13.10 tCO2e/$MAlnylam PharmaceuticalsYear: 2024Scope 1: 3,832 tCO2eRevenue: $M 2,248Scope 1 Intensity: 1.70 tCO2e/$MBeOne MedicinesYear: 2024Scope 1: 3,547 tCO2eRevenue: $M 27,369Scope 1 Intensity: 0.13 tCO2e/$MPharmaron BeijingYear: 2024Scope 1: 34,268 tCO2eRevenue: $M 1,682Scope 1 Intensity: 20.37 tCO2e/$MJacobio Pharmaceuticals GroupYear: 2023Scope 1: 34 tCO2eRevenue: $M 10Scope 1 Intensity: 3.48 tCO2e/$MAsymchem Laboratories (Tianjin)Year: 2023Scope 1: 46,854 tCO2eRevenue: $M 1,101Scope 1 Intensity: 42.55 tCO2e/$MValnevaYear: 2024Scope 1: 1,277 tCO2eRevenue: $M 176Scope 1 Intensity: 7.24 tCO2e/$MWuXi Biologics (Cayman)Year: 2023Scope 1: 32,687 tCO2eRevenue: $M 2,603Scope 1 Intensity: 12.56 tCO2e/$MAlphamab OncologyYear: 2023Scope 1: 3,970 tCO2eRevenue: $M 34Scope 1 Intensity: 117.90 tCO2e/$MBioMarin PharmaceuticalYear: 2022Scope 1: 14,000 tCO2eRevenue: $M 2,096Scope 1 Intensity: 6.68 tCO2e/$MGenor Biopharma HoldingsYear: 2022Scope 1: 18 tCO2eRevenue: $M 3Scope 1 Intensity: 7.17 tCO2e/$MIonis PharmaceuticalsYear: 2024Scope 1: 2,616 tCO2eRevenue: $M 705Scope 1 Intensity: 3.71 tCO2e/$MZealand PharmaYear: 2024Scope 1: 145 tCO2eRevenue: $M 9Scope 1 Intensity: 16.60 tCO2e/$MAdimmuneYear: 2023Scope 1: 4,556 tCO2eRevenue: $M 58Scope 1 Intensity: 78.30 tCO2e/$M

How does Adimmune's GHG emissions intensity compare to its peers?

In 2023, Adimmune reported a Scope 1 emissions intensity of 78.3 tCO₂e per millions USD. Compared to the peer group median of 6.68 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a

Where does Adimmune rank on GHG emissions intensity within its industry?

In 2023, Adimmune ranked 20 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a

This places Adimmune among the least efficient performers, with one of the highest emissions intensities in its sector. a

Want Full Access to Adimmune's GHG Emissions Dataset?
Sign Up